Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01445067 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01445067 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 48 participants.
The verdict
NCT01445067, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
Interventions
- DRUG BMS-927711 (CGRP Antagonist)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01445067
The ClinicalTrials.gov registry entry for NCT01445067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-927711 (CGRP Antagonist) is the first listed.
NCT01445067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01445067 about?
NCT01445067 is a clinical study titled "Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition". The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
What is the current status of trial NCT01445067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01445067?
The interventions under investigation include: BMS-927711 (CGRP Antagonist) (DRUG).
Who is sponsoring clinical trial NCT01445067?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.